Headache as a Significant Central Nervous System Manifestation of COVID-19 Infection
International Clinical Neuroscience Journal,
Vol. 9 (2022),
10 Dey 2022
,
Page e7
Abstract
Dear Editor,
In recent years, the world has witnessed the emergence of dangerous respiratory diseases with coronaviruses, including the severe acute respiratory syndrome (SARS) by the SARS-CoV, Middle East respiratory syndrome (MERS) by the MERS-CoV, and coronavirus disease 2019 (COVID-19) by the SARS-CoV-2. The disease now affects most countries in the world. Coronavirus is generally known to cause respiratory disease, but clinical and experimental studies show that this disorder affects several organs including the central nervous system (CNS).1-3
The CNS effects of COVID-19 are not well-known owing to being an emerging phenomenon, however, it is worth understanding. The virus enters the cells of the human body using the cellular receptor angiotensin-converting enzyme 2 (ACE2). In a normal condition, this receptor is expressed in very small amounts in the CNS. The virus can be transmitted to the CNS through systemic circulation or across the cribriform plate of the ethmoid bone in the early and secondary stages of COVID-19 infection. Broad spectrum of neurological manifestations such as ageusia, anosmia, headache, sensory disturbances and epilepsy have been observed in some patients. Anosmia and ageusia are common, and can occur in the absence of other clinical features. Unexpectedly, acute cerebrovascular disease due to hyper coagulation state is also emerging as an important complication. Altered level of consciousness and encephalitis are other presentations in patients with COVID-19.4,5 Almost all the articles reviewed focused on macro-and microscopic changes in the lungs, and only a handful of information from other organs and systemic findings were presented. Comprehensive study after autopsy in the brain is very important and more research needs to be done.6-9 A better understanding of the function of coronavirus in the CNS and accurate identification of the damage can help in treatment planning and prognosis of the disease.10,11 In addition, hypoxia may occur in the CNS (hypoxic ischemic encephalopathy) due to respiratory failure. Thrombotic microangiopathy can also occur.12 Hence, it is of paramount importance that in the early and uncomplicated stages of coronavirus infection, the patient’s CNS be examined. There is still insufficient information to provide a complete picture of the pathophysiology of SARS-CoV-2 infection. Careful clinical, diagnostic, and epidemiological studies are needed to help define the manifestations and burden of neurological disease caused by SARS-CoV-2. Precise case definitions must be used to distinguish non-specific complications of severe disease (e.g. hypoxic encephalopathy and critical care neuropathy).4 In light of the above mentioned, further studies on patients with progressive or worsening CNS findings should be performed more carefully to make the undiscovered effects of this virus on the CNS clearer to the world.
So far, we have mentioned CNS involvement in general and now we aim to give a brief summary of studies on headache attributed to COVID-19 infection. The reports on the neurological presentations are rising significantly and headache has the lead on the symptom list.
Headache associated with systemic infections is usually nonspecific and actually there are no particular distinguishing or characteristic features. It was reported that headache was a frequent symptom in COVID-19 infection and there was an extreme diversity in its characteristics.
- Covid-19
- CNS
- encephalititis
- SARS-CoV-2
How to Cite
References
Desforges M, Le Coupanec A, Brison E, Meessen-Pinard M, Talbot PJ. Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans. Adv Exp Med Biol. 2014;807:75-96. doi: 10.1007/978-81-322- 1777-0_6.
Lau KK, Yu WC, Chu CM, Lau ST, Sheng B, Yuen KY. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis. 2004;10(2):342-4. doi: 10.3201/eid1002.030638.
Bergmann CC, Lane TE, Stohlman SA. Coronavirus infection of the central nervous system: host-virus stand-off. Nat Rev Microbiol. 2006;4(2):121-32. doi: 10.1038/nrmicro1343.
Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767-83. doi: 10.1016/s1474-4422(20)30221-0.
Shahjouei S, Tsivgoulis G, Farahmand G, Koza E, Mowla A, Vafaei Sadr A, et al. SARS-CoV-2 and stroke characteristics: a report from the multinational COVID-19 Stroke Study Group. Stroke. 2021;52(5):e117-e30. doi: 10.1161/ strokeaha.120.032927.
Hanley B, Lucas SB, Youd E, Swift B, Osborn M. Autopsy in suspected COVID-19 cases. J Clin Pathol. 2020;73(5):239-42. doi: 10.1136/jclinpath-2020-206522.
Osborn M, Lucas S, Stewart R, Swift B, Youd E. Autopsy Practice Relating to Possible Cases of COVID-19 (2019- nCov, Novel Coronavirus from China 2019/2020). The Royal College of Pathologists; 2020.
Basso C, Calabrese F, Sbaraglia M, Del Vecchio C, Carretta G, Saieva A, et al. Feasibility of postmortem examination in the era of COVID-19 pandemic: the experience of a Northeast Italy University Hospital. Virchows Arch. 2020;477(3):341-7. doi: 10.1007/s00428-020-02861-1.
Fineschi V, Aprile A, Aquila I, Arcangeli M, Asmundo A, Bacci M, et al. Management of the corpse with suspect, probable or confirmed COVID-19 respiratory infection - Italian interim recommendations for personnel potentially exposed to material from corpses, including body fluids, in morgue structures and during autopsy practice. Pathologica. 2020;112(2):64-77. doi: 10.32074/1591-951x-13-20.
Cataldi M, Pignataro G, Taglialatela M. Neurobiology of coronaviruses: potential relevance for COVID-19. Neurobiol Dis. 2020;143:105007. doi: 10.1016/j.nbd.2020.105007.
Al-Kuraishy HM, Al-Gareeb AI, Monteiro MC, Al-Saiddy HJ. Brain injury and SARS-CoV-2 infection: bidirectional pathways. Curr Med Drug Res. 2020;4(2):207.
Luostarinen T, Virta J, Satopää J, Bäcklund M, Kivisaari R, Korja M, et al. Intensive care of traumatic brain injury and aneurysmal subarachnoid hemorrhage in Helsinki during the COVID-19 pandemic. Acta Neurochir (Wien). 2020;162(11):2715-24. doi: 10.1007/s00701-020-04583-4.
Toptan T, Aktan Ç, Başarı A, Bolay H. Case series of headache characteristics in COVID-19: headache can be an isolated symptom. Headache. 2020;60(8):1788-92. doi: 10.1111/ head.13940.
Bolay H, Gül A, Baykan B. COVID-19 is a real headache! Headache. 2020;60(7):1415-21. doi: 10.1111/head.13856.
Rocha-Filho PAS, Magalhães JE. Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia. Cephalalgia. 2020;40(13):1443-51. doi: 10.1177/0333102420966770.
Magdy R, Hussein M, Ragaie C, Abdel-Hamid HM, Khallaf A, Rizk HI, et al. Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: a cross sectional study. Cephalalgia. 2020;40(13):1422-31. doi: 10.1177/0333102420965140.
Al-Hashel JY, Abokalawa F, Alenzi M, Alroughani R, Ahmed SF. Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study. J Headache Pain. 2021;22(1):97. doi: 10.1186/s10194- 021-01314-7.
García-Azorín D, Sierra Á, Trigo J, Alberdi A, Blanco M, Calcerrada I, et al. Frequency and phenotype of headache in COVID-19: a study of 2194 patients. Sci Rep. 2021;11(1):14674. doi: 10.1038/s41598-021-94220-6.
Caronna E, Pozo-Rosich P. Headache during COVID-19: lessons for all, implications for the International Classification of Headache Disorders. Headache. 2021;61(2):385-6. doi: 10.1111/head.14059.
- Abstract Viewed: 363 times
- PDF Downloaded: 415 times